Cargando…

2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma

The primary cutaneous lymphomas are often indolent but difficult to treat. In the early stages psoralen and ultraviolet-A therapy is the standard treatment whereas at the tumor stage chemotherapy (e.g. pegylated doxorubicin) is often used for debulking. The purine analog 2-chlorodeoxyadenosine (2CdA...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokołowska-Wojdyło, Małgorzata, Trzeciak, Magdalena, Roszkiewicz, Jadwiga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211472/
https://www.ncbi.nlm.nih.gov/pubmed/25386249
http://dx.doi.org/10.4081/dr.2010.e12
_version_ 1782341573260869632
author Sokołowska-Wojdyło, Małgorzata
Trzeciak, Magdalena
Roszkiewicz, Jadwiga
author_facet Sokołowska-Wojdyło, Małgorzata
Trzeciak, Magdalena
Roszkiewicz, Jadwiga
author_sort Sokołowska-Wojdyło, Małgorzata
collection PubMed
description The primary cutaneous lymphomas are often indolent but difficult to treat. In the early stages psoralen and ultraviolet-A therapy is the standard treatment whereas at the tumor stage chemotherapy (e.g. pegylated doxorubicin) is often used for debulking. The purine analog 2-chlorodeoxyadenosine (2CdA) acts in non-Hodgkin’s lymphoma and has been used in our center for the treatment of advanced primary cutaneous T-cell lyphomas (CTCL). Here, we report on the efficacy and side effects of 2CdA in six patients with CTCL. One patient died owing to myelosuppression. Partial responses were seen in four cases but full remission was observed in only one case. We concluded that 2CdA has a limited usefulness in the management of advanced CTCL.
format Online
Article
Text
id pubmed-4211472
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher PAGEPress Publications
record_format MEDLINE/PubMed
spelling pubmed-42114722014-11-10 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma Sokołowska-Wojdyło, Małgorzata Trzeciak, Magdalena Roszkiewicz, Jadwiga Dermatol Reports Article The primary cutaneous lymphomas are often indolent but difficult to treat. In the early stages psoralen and ultraviolet-A therapy is the standard treatment whereas at the tumor stage chemotherapy (e.g. pegylated doxorubicin) is often used for debulking. The purine analog 2-chlorodeoxyadenosine (2CdA) acts in non-Hodgkin’s lymphoma and has been used in our center for the treatment of advanced primary cutaneous T-cell lyphomas (CTCL). Here, we report on the efficacy and side effects of 2CdA in six patients with CTCL. One patient died owing to myelosuppression. Partial responses were seen in four cases but full remission was observed in only one case. We concluded that 2CdA has a limited usefulness in the management of advanced CTCL. PAGEPress Publications 2010-09-02 /pmc/articles/PMC4211472/ /pubmed/25386249 http://dx.doi.org/10.4081/dr.2010.e12 Text en ©Copyright M. Sokołowska-Wojdyło et al., 2010 This work is licensed under a Creative Commons Attribution 3.0 License (by-nc 3.0). Licensee PAGEPress, Italy
spellingShingle Article
Sokołowska-Wojdyło, Małgorzata
Trzeciak, Magdalena
Roszkiewicz, Jadwiga
2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma
title 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma
title_full 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma
title_fullStr 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma
title_full_unstemmed 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma
title_short 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma
title_sort 2-chlorodeoxyadenosine treatment for cutaneous t-cell lymphoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211472/
https://www.ncbi.nlm.nih.gov/pubmed/25386249
http://dx.doi.org/10.4081/dr.2010.e12
work_keys_str_mv AT sokołowskawojdyłomałgorzata 2chlorodeoxyadenosinetreatmentforcutaneoustcelllymphoma
AT trzeciakmagdalena 2chlorodeoxyadenosinetreatmentforcutaneoustcelllymphoma
AT roszkiewiczjadwiga 2chlorodeoxyadenosinetreatmentforcutaneoustcelllymphoma